Perigon Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

Perigon Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,554	Closed	-$282K	–	713
2022 Q3	$282K	Sell	2,554 -500	-16%	-$50.4K	0.02%	435
2022 Q2	$229K	Buy	3,054 +10	+0.3%	+$736	0.02%	504
2022 Q1	$238K	Sell	3,044 -3	-0.1%	-$230	0.02%	540
2021 Q4	$274K	Buy	3,047 +4	+0.1%	+$342	0.02%	471
2021 Q3	$281K	Buy	3,043 +115	+4%	+$8.86K	0.02%	435
2021 Q2	$228K	Buy	2,928 +10	+0.3%	+$758	0.02%	469
2021 Q1	$217K	Buy	2,918 +409	+16%	+$37.7K	0.02%	455
2020 Q4	$428K	Buy	2,509 +4	+0.2%	+$593	0.05%	275
2020 Q3	$352K	Sell	2,505 -1,195	-32%	-$182K	0.05%	277
2020 Q2	$593K	Hold	3,700	–	–	0.09%	173
2020 Q1	$402K	Buy	+3,700	New	+$423K	0.07%	197
2018 Q4	–	Sell	-5,503	Closed	-$889K	–	272
2018 Q3	$889K	Buy	+5,503	New	+$752K	0.22%	82

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perigon Wealth Management's SRPT Position: Q4 2022 in Review

Perigon Wealth Management sold out of Sarepta Therapeutics (SRPT) in Q4 2022, closing a stake of 2,554 shares — an estimated $282K sold.

Perigon Wealth Management first reported a position in SRPT in Q3 2018 and held it in 12 quarters. The position peaked at $889K in Q3 2018. 411 funds tracked by Wall St. Rank hold SRPT as of Q4 2022.

Perigon Wealth Management reported no remaining Sarepta Therapeutics position as of Q4 2022 after selling out during the quarter.
Perigon Wealth Management sold 2,554 Sarepta Therapeutics shares in Q4 2022, an estimated $282K.
Perigon Wealth Management first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 12 quarters.
Perigon Wealth Management's Sarepta Therapeutics position peaked at $889K in Q3 2018.
411 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2022.

Based on Perigon Wealth Management's 13F filing for Q4 2022, filed 14 Feb 2023.